Login Register Cart 0
Review Article

抗击 COVID-19 战争中药物治疗的证据和主要不良反应

卷 28, 期 16, 2021

发表于: 26 October, 2020

页: [3147 - 3157] 页: 11

弟呕挨: 10.2174/0929867327666201026145630

价格: $65

摘要

背景：如今，全球 COVID-19 大流行的突破是临床医生面临的最大健康挑战，它代表着为这些患者确定有效治疗方法的意外努力。目前还没有针对这种感染的经过证实的确定性疗法。不幸的是，受感染的患者每天都在以惊人的方式增加，比医学证据还快。目前，关于 SARS-COV-2 病毒学的不断扩展的知识提供了几个潜在的药物靶点。 目标：因此，临床医生需要快速审查和指导大多数处方药物的主要不良反应，特别是在医院护理期间每种药物治疗的疗效和潜在风险。 方法：使用 PubMed 进行文章审查，以确定截至 2020 年 7 月 20 日报告的英文相关论文；使用 Web of Science 进行了第二次审查，直到 2020 年 8 月 28 日。由于缺乏随机临床试验，我们纳入了病例报告、病例系列和审查。我们一共找到了1606篇相关文章。作者独立审查了标题和摘要以供收录。 结论：目前，尽管为发表多项试验或病例报告付出了巨大的医学努力，但我们尚未发现针对 COVID-19 感染的明确疗法。这篇简短的综述旨在以迄今为止提出的部分证据，从与治疗相关的系统观点中，迅速识别风险因素和主要不良反应。

关键词: COVID-19 大流行、SARS-COV-2、感染、随机临床试验、确定性疗法、治疗。

« Previous Next »
[1]
Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020, 382(8), 727-733.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[2]
Yao, X.; Ye, F.; Zhang, M.; Cui, C.; Huang, B.; Niu, P.; Liu, X.; Zhao, L.; Dong, E.; Song, C.; Zhan, S.; Lu, R.; Li, H.; Tan, W.; Liu, D. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis., 2020, 71(15), 732-739.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[3]
World Health Organization. The Cardiotoxicity of Antimalarials, 2017. Available at: https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf (Accessed: April, 2020).
[4]
US Food and Drug Administration. Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease, 2020. Available at: https://www.fda.gov/media/136534/download (Accessed: April, 2020).
[5]
Centers for Disease Control and Prevention. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19, 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html (Accessed: April, 2020).
[6]
Gautret, P.; Lagier, J.C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Tissot Dupont, H.; Honoré, S.; Colson, P.; Chabrière, E.; La Scola, B.; Rolain, J.M.; Brouqui, P.; Raoult, D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 2020, 56(1), 105949.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[7]
Chen, J.; Liu, D.; Liu, L.; Liu, P.; Xu, Q.; Xia, L.; Ling, Y.; Huang, D.; Song, S.; Zhang, D.; Qian, Z.; Li, T.; Shen, Y.; Lu, H. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2020, 49(2), 215-219.
[http://dx.doi.org/10.3785/j.issn.1008-9292.2020.03.03] [PMID: 32391667]
[8]
Molina, J.M.; Delaugerre, C.; Le Goff, J.; Mela-Lima, B.; Ponscarme, D.; Goldwirt, L.; de Castro, N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med. Mal. Infect., 2020, 50(4), 384.
[http://dx.doi.org/10.1016/j.medmal.2020.03.006] [PMID: 32240719]
[9]
Cavalcanti, A.B.; Zampieri, F.G.; Rosa, R.G.; Azevedo, L.C.P.; Veiga, V.C.; Avezum, A.; Damiani, L.P.; Marcadenti, A.; Kawano-Dourado, L.; Lisboa, T.; Junqueira, D.L.M.; de Barros E Silva, P.G.M.; Tramujas, L.; Abreu-Silva, E.O.; Laranjeira, L.N.; Soares, A.T.; Echenique, L.S.; Pereira, A.J.; Freitas, F.G.R.; Gebara, O.C.E.; Dantas, V.C.S.; Furtado, R.H.M.; Milan, E.P.; Golin, N.A.; Cardoso, F.F.; Maia, I.S.; Hoffmann Filho, C.R.; Kormann, A.P.M.; Amazonas, R.B.; Bocchi de Oliveira, M.F.; Serpa-Neto, A.; Falavigna, M.; Lopes, R.D.; Machado, F.R.; Berwanger, O. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N. Engl. J. Med., 2020, 383(21), 2041-2052.
[http://dx.doi.org/10.1056/NEJMoa2019014] [PMID: 32706953]
[10]
Tisdale, J.E.; Jaynes, H.A.; Kingery, J.R.; Mourad, N.A.; Trujillo, T.N.; Overholser, B.R.; Kovacs, R.J. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ. Cardiovasc. Qual. Outcomes, 2013, 6(4), 479-487.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.113.000152] [PMID: 23716032]
[11]
Chugh, S.S.; Reinier, K.; Singh, T.; Uy-Evanado, A.; Socoteanu, C.; Peters, D.; Mariani, R.; Gunson, K.; Jui, J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation, 2009, 119(5), 663-670.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.797035] [PMID: 19171855]
[12]
Sapp, J.L.; Alqarawi, W.; MacIntyre, C.J.; Tadros, R.; Steinberg, C.; Roberts, J.D.; Laksman, Z.; Healey, J.S.; Krahn, A.D. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of covid-19: a statement from the Canadian Heart Rhythm Society. Can. J. Cardiol., 2020, 36(6), 948-951.
[http://dx.doi.org/10.1016/j.cjca.2020.04.003] [PMID: 32299753]
[13]
Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N. Engl. J. Med., 2020, 382(19), 1787-1799.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[14]
Bernstein, B.; King, M.; Brun, S.; Cernohous, P.; Potthoff, A.; Moseley, J.; Sullivan, M.; Grebner, K.; Sun, E. Safety of Kaletra: data from phase II and phase III clinical trials. In: 1st International AIDS Society Conference on HIV Pathogenesis & Treatment, 2001.
[15]
Cupp, M.J.; Tracy, T.S. Cytochrome P450: new nomenclature and clinical implications. Am. Fam. Physician, 1998, 57(1), 107-116.
[PMID: 9447218]
[16]
World Health Organization. WHO R&D blueprint: ad-hoc expert consultation on clinical trials for Ebola therapeutics, 2018. Available at: https://www.who.int/ebola/drc-2018/treatments-approved-for-compassionate-use-update/en/ (Accessed: August, 2020).
[17]
Grein, J.; Ohmagari, N.; Shin, D.; Diaz, G.; Asperges, E.; Castagna, A.; Feldt, T.; Green, G.; Green, M.L.; Lescure, F.X.; Nicastri, E.; Oda, R.; Yo, K.; Quiros-Roldan, E.; Studemeister, A.; Redinski, J.; Ahmed, S.; Bernett, J.; Chelliah, D.; Chen, D.; Chihara, S.; Cohen, S.H.; Cunningham, J.; D’Arminio Monforte, A.; Ismail, S.; Kato, H.; Lapadula, G.; L’Her, E.; Maeno, T.; Majumder, S.; Massari, M.; Mora-Rillo, M.; Mutoh, Y.; Nguyen, D.; Verweij, E.; Zoufaly, A.; Osinusi, A.O.; DeZure, A.; Zhao, Y.; Zhong, L.; Chokkalingam, A.; Elboudwarej, E.; Telep, L.; Timbs, L.; Henne, I.; Sellers, S.; Cao, H.; Tan, S.K.; Winterbourne, L.; Desai, P.; Mera, R.; Gaggar, A.; Myers, R.P.; Brainard, D.M.; Childs, R.; Flanigan, T. Compassionate use of remdesivir for patients with severe covid-19. N. Engl. J. Med., 2020, 382(24), 2327-2336.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[18]
Avirutnan, P. Efficacy and Safety of Ivermectin against Dengue Infection: A Phase III, Randomized, Double-blind, Placebo-controlled Trial, 2015. NCT Trial NCT02045069, Available at: https:// clinicaltrials.gov/ct2/show/NCT02045069 (Accessed: April, 2020).
[19]
Poyiadji, N.; Shahin, G.; Noujaim, D.; Stone, M.; Patel, S.; Griffith, B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology, 2020, 296(2), E119-E120.
[http://dx.doi.org/10.1148/radiol.2020201187] [PMID: 32228363]
[20]
Martinon, F.; Pétrilli, V.; Mayor, A.; Tardivel, A.; Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 2006, 440(7081), 237-241.
[http://dx.doi.org/10.1038/nature04516] [PMID: 16407889]
[21]
Shi, C.-S.; Nabar, N.R.; Huang, N-N.; Kehrl, J.H. SARS- Coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov., 2019, 5, 101.
[http://dx.doi.org/10.1038/s41420-019-0181-7] [PMID: 31231549]
[22]
Chen, I.-Y.; Moriyama, M.; Chang, M.-F.; Ichinohe, T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front. Microbiol., 2019, 10, 50.
[http://dx.doi.org/10.3389/fmicb.2019.00050] [PMID: 30761102]
[23]
Karakike, E.; Giamarellos-Bourboulis, E.J. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front. Immunol., 2019, 10, 55.
[http://dx.doi.org/10.3389/fimmu.2019.00055] [PMID: 30766533]
[24]
Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223), 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[25]
Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med., 2020, 46(5), 846-848.
[http://dx.doi.org/10.1007/s00134-020-05991-x] [PMID: 32125452]
[26]
Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19), 2020. Available at: http://www.chictr.org.cn/ (Accessed: September, 2020).
[27]
Mair-Jenkins, J.; Saavedra-Campos, M.; Baillie, J.K.; Cleary, P.; Khaw, F.M.; Lim, W.S.; Makki, S.; Rooney, K.D.; Nguyen-Van-Tam, J.S.; Beck, C.R. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis., 2015, 211(1), 80-90.
[http://dx.doi.org/10.1093/infdis/jiu396] [PMID: 25030060]
[28]
Cao, W.; Liu, X.; Bai, T.; Fan, H.; Hong, K.; Song, H.; Han, Y.; Lin, L.; Ruan, L.; Li, T. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect. Dis., 2020, 7(3), ofaa102.
[http://dx.doi.org/10.1093/ofid/ofaa102] [PMID: 32258207]
[29]
Stiehm, E.R. Adverse effects of human immunoglobulin therapy. Transfus. Med. Rev., 2013, 27(3), 171-178.
[http://dx.doi.org/10.1016/j.tmrv.2013.05.004] [PMID: 23835249]
[30]
Imbach, P.; Barandun, S.; d’Apuzzo, V.; Baumgartner, C.; Hirt, A.; Morell, A.; Rossi, E.; Schöni, M.; Vest, M.; Wagner, H.P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet, 1981, 1(8232), 1228-1231.
[http://dx.doi.org/10.1016/S0140-6736(81)92400-4] [PMID: 6112565]
[31]
Orbach, H.; Katz, U.; Sherer, Y.; Shoenfeld, Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin. Rev. Allergy Immunol., 2005, 29(3), 173-184.
[http://dx.doi.org/10.1385/CRIAI:29:3:173] [PMID: 16391392]
[32]
Russell, C.D.; Millar, J.E.; Baillie, J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020, 395(10223), 473-475.
[http://dx.doi.org/10.1016/S0140-6736(20)30317-2] [PMID: 32043983]
[33]
World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance: Patient management, 2019. Available at: https://www.who.int/emergencies/diseases/novel- coronavirus-2019/technical-guidance/patient-management (Accessed: September, 2020).
[34]
Xu, Z.; Shi, L; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; Tai, Y.; Bai, C.; Gao, T.; Song, J.; Xia, P.; Dong, J.; Zhao, J.; Wang, F.S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Med., 2020, 8(4), 420-422.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[35]
Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y.; Song, J.; Wang, S.; Chao, Y.; Yang, Z.; Xu, J.; Zhou, X.; Chen, D.; Xiong, W.; Xu, L.; Zhou, F.; Jiang, J.; Bai, C.; Zheng, J.; Song, Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med., 2020, 180(7), 934-943.
[http://dx.doi.org/10.1001/jamainternmed.2020.0994] [PMID: 32167524]
[36]
Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Chappell, L.C.; Faust, S.N.; Jaki, T.; Jeffery, K.; Montgomery, A.; Rowan, K.; Juszczak, E.; Baillie, J.K.; Haynes, R.; Landray, M.J. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med., 2021, 384(8), 693-704.
[http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]
[37]
Migita, K.; Arai, T.; Ishizuka, N.; Jiuchi, Y.; Sasaki, Y.; Izumi, Y.; Kiyokawa, T.; Suematsu, E.; Miyamura, T.; Tsutani, H.; Kawabe, Y.; Matsumura, R.; Mori, S.; Ohshima, S.; Yoshizawa, S.; Kawakami, K.; Suenaga, Y.; Nishimura, H.; Sugimoto, T.; Iwase, H.; Sawada, H.; Yamashita, H.; Kuratsu, S.; Ogushi, F.; Kawabata, M.; Matsui, T.; Furukawa, H.; Bito, S.; Tohma, S. Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy. PLoS One, 2013, 8(11), e78699.
[http://dx.doi.org/10.1371/journal.pone.0078699] [PMID: 24260127]
[38]
Singh, A.V.; Laux, P.; Lunch, A.; Balkrishnan, S.; Dakua, S.P. Bottom-UP assembly of nanorobots: extending synthetic biology to complex material design. Front. Nanosci. Nanotechnol., 2019, 5, 1, 2.
[http://dx.doi.org/10.15761/FNN.1000S2005]
[39]
Jácome, R.; Campillo-Balderas, J.A.; Ponce de León, S.; Becerra, A.; Lazcano, A. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci. Rep., 2020, 10(1), 9294.
[http://dx.doi.org/10.1038/s41598-020-66440-9] [PMID: 32518317]
[40]
Singh, A.V.; Ansari, M.H.D.; Laux, P.; Luch, A. Micro- nanorobots: important considerations when developing novel drug delivery platforms. Expert Opin. Drug Deliv., 2019, 16(11), 1259-1275.
[http://dx.doi.org/10.1080/17425247.2019.1676228] [PMID: 31580731]
[41]
Singh, A.V.; Batuwangala, M.; Mundra, R.; Mehta, K.; Patke, S.; Falletta, E.; Patil, R.; Gade, W.N. Biomineralized anisotropic gold microplate-macrophage interactions reveal frustrated phagocytosis-like phenomenon: a novel paclitaxel drug delivery vehicle. ACS Appl. Mater. Interfaces, 2014, 6(16), 14679-14689.
[http://dx.doi.org/10.1021/am504051b] [PMID: 25046687]
[42]
Keech, C.; Albert, G.; Cho, I.; Robertson, A.; Reed, P.; Neal, S.; Plested, J.S.; Zhu, M.; Cloney-Clark, S.; Zhou, H.; Smith, G.; Patel, N.; Frieman, M.B.; Haupt, R.E.; Logue, J.; McGrath, M.; Weston, S.; Piedra, P.A.; Desai, C.; Callahan, K.; Lewis, M.; Price-Abbott, P.; Formica, N.; Shinde, V.; Fries, L.; Lickliter, J.D.; Griffin, P.; Wilkinson, B.; Glenn, G.M. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med., 2020, 383(24), 2320-2332.
[http://dx.doi.org/10.1056/NEJMoa2026920] [PMID: 32877576]
[43]
Dang, D.; Wang, L.; Zhang, C.; Li, Z.; Wu, H. Potential effects of SARS-CoV-2 infection during pregnancy on fetuses and newborns are worthy of attention. J. Obstet. Gynaecol. Res., 2020, 46(10), 1951-1957.
[http://dx.doi.org/10.1111/jog.14406] [PMID: 32779309]
[44]
Favilli, A.; Mattei Gentili, M.; Raspa, F.; Giardina, I.; Parazzini, F.; Vitagliano, A.; Borisova, A.V.; Gerli, S. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. J. Matern. Fetal Neonatal Med., 2020, 1-14.
[http://dx.doi.org/10.1080/14767058.2020.1774875] [PMID: 32508168]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy